Evidence map›Paper›PMID 32835353›Full record

ReviewBJUI compass2020

The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview.

Nathan A Brooks, Vikram Narayan, Paul K Hegarty, Helen Zafirakis, Xiang-Yang Han, Ashish M Kamat

4 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in BJUI compass, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04327206 phase3completednot on this map

BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial

TypeinterventionalSponsorMurdoch Childrens Research InstituteRan2020 to 2022Enrolled6,828ConditionsCoronavirus Disease 2019 (COVID-19), Respiratory Illness, Corona Virus Infection, COVID-19ArmsBCG Vaccine, 0.9%NaCl
NCT04328441 phase3completednot on this map

Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial.

TypeinterventionalSponsorUMC UtrechtRan2020 to 2021Enrolled1,511ConditionsCOVID-19ArmsBCG Vaccine, Placebo
NCT04348370 phase4completednot on this map

Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses

TypeinterventionalSponsorTexas A&M UniversityRan2020 to 2023Enrolled659ConditionsCoronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified ElsewhereArmsBCG Vaccine, Placebo Vaccine
NCT04350931 phase3unknown statusnot on this map

Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19

TypeinterventionalSponsorAin Shams UniversityRan2020 to 2020Enrolled900ConditionsCoronavirus Disease (COVID-19)Armsintradermal injection of BCG Vaccine, placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. COVID-19 and BCG: where's the challenge?World journal of urology · 2022
    Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nathan A BrooksDepartment of Urology The University of Texas MD Anderson Cancer Center Houston TX USA.ORCID https://orcid.org/0000-0002-5111-6914
Vikram NarayanDepartment of Urology The University of Texas MD Anderson Cancer Center Houston TX USA.ORCID https://orcid.org/0000-0003-3731-4209
Paul K HegartyDepartment of Urology Mater Private Hospital Dublin Ireland.
Helen ZafirakisDepartment of Urology Mater Private Hospital Dublin Ireland.
Xiang-Yang HanDepartment of Pathology and Laboratory Medicine MD Anderson Cancer Center The University of Texas Houston TX USA.
Ashish M KamatDepartment of Urology The University of Texas MD Anderson Cancer Center Houston TX USA.
The University of Texas MD Anderson Cancer Center · USMater Misericordiae University Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo summarize the available literature regarding bacillus Calmette-Guerin (BCG) administration, severe acute respiratory syndrome conoravirus-2 (SARS-CoV-2), and the resulting clinical condition coronavirus disease (COVID-19) in light of recent epidemiologic work suggesting decreased infection severity in BCG immunized populations while highlighting the potential role of the urologist in clinical trials and ongoing research efforts. MATERIALS AND

methodsWe reviewed the available literature regarding COVID-19 and BCG vaccination. Specifically, the epidemiologic evidence for decreased COVID-19 morbidity in countries with BCG vaccination programs, current clinical trials for BCG vaccination to protect against COVID-19, potential mechanisms and rationale for this protection, and the role of the urologist and urology clinic in providing support and/or leading ongoing efforts.

resultsEpidemiologic evidence suggests that the crude case fatality rates are lower for countries with BCG vaccination compared to those without such programs. Four prospective, randomized clinical trials for BCG vaccination were identified including NCT04348370 (BADAS), NCT04327206 (BRACE), NCT04328441 (BCG-CORONA), and NCT04350931. BCG administration may contribute to innate and adaptive immune priming with several opportunities for translational research.

conclusionsThe urologist's expertise with BCG and the infrastructure of urologic clinics may afford several opportunities for collaboration and leadership to evaluate and understand the potential role of BCG in the current COVID-19 pandemic.

Indexed as

bacillus Calmette-GuerinBCGCOVID-19SARS-CoV-2

Identifiers

PMID32835353
PMCPMC7361196
OpenAlexW3036393438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.